RethinkPeptides

Amylin Analogs

Explore peptide research and guides on amylin analogs.

Cagrilintide: Amylin Reimagined for GLP-1

Cagrilintide is a long-acting amylin analog that achieved 20.4% weight loss combined with semaglutide in the REDEFINE 1 Phase 3 trial of 3,417 adults.

Amylin Analogs

Pramlintide: Why This Diabetes Drug Failed

Pramlintide (Symlin) is the only FDA-approved amylin analog for diabetes. It works, but dosing complexity and GLP-1 drug competition killed adoption.

Amylin Analogs

Amylin + GLP-1 Combinations for Obesity

CagriSema combines cagrilintide (amylin) and semaglutide (GLP-1) for 20.4% weight loss in phase 3 trials. The science behind dual-hormone obesity treatment.